NCT04570410View on ClinicalTrials.gov

Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

April 15, 2024

Study Completion Date

April 15, 2024

Conditions
Bladder Urothelial Carcinoma
Interventions
PROCEDURE

primary focal resection plus lymph node dissection

Primary radical resection plus lymph node dissection was performed in patients with oligometastatic urothelial carcinoma

DRUG

Tislelizumab

Tislelizumab IV infusion of 200 mg Q3W

DRUG

Gemcitabine plus cisplatin

GC (Gemcitabine plus cisplatin): Gemcitabine 1000mg/m2 D1,D8 iv every 3 weeks Cisplatin70mg/m2,D2,3,4 iv every 3 weeks

Trial Locations (1)

210000

The first affiliated hospital of Nanjing Medical University, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER

NCT04570410 - Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial Carcinoma | Biotech Hunter | Biotech Hunter